The features of the liver function tests in patients with COVID-19
AbstractIt is known that SARS-CoV-2 can cause liver damage due to the tropism of the virus to cholangiocytes and hepatocytes, the development of a cytokine storm, organ ischemia, aggravated in existing chronic liver disease and increasing during hospitalization, which probably can be related to the current drug intake or comorbidity. Evaluation of the frequency of abnormal liver function tests prior to the drugs administration in the hospital would allow to exclude a possible toxic effect.
Aim of the study is to establish the prevalence and features of liver function tests (LFT) abnormalities and factors associated with in hospitalized patients with COVID-19.
Methods. 248 adult patients with confirmed COVID-19 were admitted to the infectious diseases hospital were selected for an observational cross-sectional study. Patients clinical and laboratory characteristics, the frequency of liver damage are presented, and the relationship with such risk factors as age, gender, comorbidity, prehospital drug intake, COVID-19 severity, oxygen saturation (SaO2), need for admission in intensive care unit is assessed.
Results. 41.2% of patients with COVID-19 had LFT abnormalities at the time of admission. Liver damage, represented mainly by cholestatic (76.9%) and hepatocellular (27.4%) patterns, was mild in the most cases. Patients over 50 years were more than twice as likely to show liver damage compared to younger patients (OR 2.24, 95% CI 1.03–4.9). There were no differences in the frequency of liver damage in patients depending on gender (OR 1.3, 95% CI 0.74–2.27), comorbidity (OR 0.91, 95% CI 0.5–1.6), pregnancy (OR 0.85, 95% CI 0.45–1.7), taking drugs before hospitalization (OR 1.3, 95% CI 0.6–2.7), including based on the drugs hepatotoxicity. The prevalence of LFT abnormalities is almost twice as high in patients with severe COVID-19 (OR 1.9, 95% CI 1.1–3.4), not associated with the level of hypoxia (OR 0.7, 95% CI 0.1–7.8), and the need for intensive care (OR 2.8, 95% CI 0.3–32.4).
Conclusion. As a result of the study, it was found that at the time of admission to the hospital, most patients with COVID-19 have mild LFT abnormalities, which increase with age and severity of COVID-19. A cohort study should be conducted to overcome the limitations of the current cross-sectional study and draw more definitive conclusions.
Keywords:COVID-19; SARS-CoV-2; liver injury; liver function tests
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
Contribution. Idea and study design – Fazylov V.Kh., Oleynik A.F.; literature review – Oleynik A.F., Revathy C.G.; database – Akifev V.O., Fayyadh A.M.; statistical analysis – Abdullah O.F., Oleynik A.F.; conclusion – Oleynik A.F., Fazylov V.Kh., Abdullah O.F.; manuscript – Oleynik A.F., Fazylov V.Kh.
For citation: Fazylov V.Kh., Oleynik A.F., Abdullah O.F., Akifev V.O., Fayyadh A.M., Revathy C.G. The features of the liver function tests in patients with COVID-19. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2022; 11 (3): 35–43. DOI: https://doi.org/10.33029/2305-3496-2022-11-3-35-43
References
1. Cai Q., Huang D., Yu H., et al. COVID-19: abnormal liver function tests. J Hepatol. 2020; 73 (3): 566–74. DOI: https://doi.org/10.1016/j.jhep.2020.04.006 Epub 2020 Apr 13. PMID: 32298767; PMCID: PMC7194951.
2. Bloom P., Meyerowitz E., Reinus Z., et al. Liver biochemistries in hospitalized patients with COVID-19. Hepatology. 2021; 73 (3): 890–900. DOI: https://doi.org/10.1002/hep.31326
3. Mao R., Qiu Y., He J., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 (7): 667–78. DOI: https://doi.org/10.1016/S2468-1253(20)30126-6
4. Qi X., Liu C., Jiang Z., et al. Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury. J Hepatol. 2020; 73 (2): 455–8. DOI: https://doi.org/10.1016/j.jhep.2020.04.010
5. Vespa E., Pugliese N., Piovani D., et al. Liver tests abnormalities in COVID-19: trick or treat? J Hepatol. 2020; 73 (5): 1275–6. DOI: https://doi.org/10.1016/j.jhep.2020.05.033
6. Wang Y., Liu S., Liu H., et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J. Hepatol. 2020; 73 (4): 807–16. DOI: https://doi.org/10.1016/j.jhep.2020.05.002
7. Zhao B., Ni C., Gao R., et al. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020; 11 (10): 771–5. DOI: https://doi.org/10.1007/s13238-020-00718-6.
8. Webb B., Peltan I., Jensen P., et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2020; 2 (12): e754–63. DOI: https://doi.org/10.1016/S2665-9913(20)30343-X
9. Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061–9. DOI: https://doi.org/10.1001/jama.2020.1585
10. Moon A., Webb G., Aloman C., et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. J Hepatol. 2020; 73 (3): 705–8. DOI: https://doi.org/10.1016/j.jhep.2020.05.013
11. Wang B., Li R., Lu Z. Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020; 12 (7): 6049–57. DOI: https://doi.org/10.18632/aging.103000
12. Channappanavar R., Fett C., Mack M., et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J Immunol. 2017; 198 (10): 4046–53. DOI: https://doi.org/10.4049/jimmunol.1601896
13. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and Other Influenza Viruses. Geneva: World Health Organization, February 2010: 20−1. URL: https://www.ncbi.nlm.nih.gov/books/NBK138515/
14. Siddiqi H., Mehra M. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020; 39 (5): 405–7. DOI: https://doi.org/10.1016/j.healun.2020.03.012
15. Grant M., Geoghegan L., Arbyn M., et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020; 15 (6): e0234765. DOI: https://doi.org/10.1371/journal.pone.0234765
16. Guan W., Ni Z., Hu Y., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708–20. DOI: https://doi.org/10.1056/NEJMoa2002032
17. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10 223): 497–506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
18. Zhang C., Shi L., Wang F. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5 (5): 428–30. DOI: https://doi.org/10.1016/S2468-1253(20)30057-1
19. Bangash M., Patel J., Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020; 5 (6): 529–30. DOI: https://doi.org/10.1016/S2468-1253(20)30084-4
20. Adams D., Hubscher S. Systemic viral infections and collateral damage in the liver. Am J Pathol. 2006; 168 (4): 1057–9. DOI: https://doi.org/10.2353/ajpath.2006.051296